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Abbreviations:  
 
AUC: Area Under the Curve   
ARID1A: AT-rich interactive domain 1A gene 
BOT: borderline tumors of the ovary 
CA125: Cancer Antigen 125   
CI: Confidence Interval   
EOC: Epithelial Ovarian Cancer   
FIGO: International Federation of Obstetricians and Gynecologists 
HRD: homologous recombination deficiency 
HGSOC: high grade serous ovarian cancer 
IDS: interval debulking surgery   
AGO Arbeitsgemeinschaft Gynäkologische Onkologie 
BRCA1/2 breast cancer gene 1/2  
ECOG Performance Status: Eastern Cooperative Oncology Group Performance 
Status 
IMO Intraoperative Mapping of Ovarian cancer 
IQR Interquartile Range 
IOTA: International Group for Ovarian Tumor Analysis 
KRAS: Kirsten rat sarcoma viral oncogene homolog 
LGSOC: low grade serous ovarian cancer 
MEK: MAPK/Erk kinase 
OS: Overall survival 
OR: Odds Ratio  
PARP:  Poly(ADP-Ribose)polymerase  
PFS: progression-free survival 
PDS: primary debulking surgery 
PIK3:  phosphatidylinositol-4,5-bisphosphate 3-kinase  
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pTEN: phosphatase and tensin homolog gene 
ROMA: risk of ovarian malignancy algorithm 
STIC: serous tubal intraepithelial carcinoma 
TOC tumor bank ovarian cancer 
TCGA The Cancer Genome Atlas  
ROCA: risk of ovarian cancer algorithm 
ROMA: risk of ovarian malignancy algorithm 
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1 Introduction 
 
Ovarian cancer is the fifth most common malignancy in women, but the first cause of 
death in the developed world due to gynecological cancer (1). The poor prognosis is 
mostly caused by late diagnosis, most of the patients (75%) being diagnosed with 
advanced FIGO III and IV stage ovarian cancer when survival rates are poor. The late 
diagnosis is caused mainly by lack of specific symptoms, of screening and early 
diagnosis tests. However the 5-years survival rates are around 80 to 90% with FIGO 
stage I ovarian cancer, compared with 40-50% in advanced stages.  
 
1.1 Etiology and molecular biology  
 
1.1.1 Etiology and molecular biology of epithelial ovarian cancer 
 
The pathogenesis of ovarian cancer is still unclear. Historically ovarian cancer was 
thought to arise from the ovarian surface epithelial. Although differences in biology, 
stage, appearance and response to therapy were known, ovarian cancer histological 
subtypes were regarded as one disease (2). Progresses have been made within the last 
years. The different histological subtypes of ovarian cancer appear to have different 
risk factors, precursor lesions, spread patterns, underlying molecular abnormalities and 
chemotherapy response (2, 3). They are now more correct regarded as different entities.  
The most common type of ovarian cancer, the high grade serous adenocarcinoma of 
the ovary (HGSOC) seems to have its origin not in the surface epithelium of the ovary, 
but from the serous tubal intraepithelial carcinoma (STIC), usually located in the 
fimbiriated distal portion of the fallopian tube (2, 4, 5). The dysplastic cells will be 
seeded on the ovarian surface and will develop further into cancer (6). The HGSOC 
are clinically characterized by extreme aggressive growth, most of the cases being 
diagnosed in advanced FIGO stages. They respond well to platinum based 
chemotherapy, but unfortunately they use to relapse, and secondary develop platinum 
resistance and consequently lead to death (7, 8). From the molecular point of view this 
subtype is characterized by high genetic instability, ubiquitary p53 loss of function 
through mutations and in 50% of the patients harbor mutations or epigenetic changes 
of HRD genes (9).  
The low grade serous ovarian cancer seem to develop from cysts (10). These will 
primary come from the incessant ovulation as postulated by Fathalla et al. (11) many 
years ago. This precursor lesion will grow slowly, and can develop into borderline 
tumors due to certain genetic aberration, and finally might transform into low grade 
ovarian cancer (10). These tumors are characterized by mutation in BRAF, KRAS and 
ERBB2. Contrary to HGSOC, LGSOC contain very few point mutations (10). From 
the clinical aspect, they are usually slower growing, usually diagnosed at early stage 
and therefore associated with better survival rates. Due to low proliferation rates, 
LGSOC are mostly platinum resistance (2). Due to lack of other standard therapies, 
most of LGSOC are treated further on with platinum based chemotherapy. A current 
study analyzing the role of MEK inhibitors as single agent therapy in LGSOC is 
ongoing (12). There is a huge unmet need to define new therapeutic strategies for 
LGSOC.  
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Endometrioid and clear cell carcinoma are the so called endometriosis related ovarian 
cancer subtypes (2).  
Endometriosis is a benign disease but there are hints that suggest that some 
endometriosis foci might transform into cancer (2). According to current data, the 
exposure to high concentrations of free iron, obtained through repeated hemorrhages 
into endometriotic cysts, is a possible cause of carcinogenesis that will lead to 
endometrioid or clear cell ovarian cancer (13).  
Clear cell carcinoma of the ovary has a distinct molecular biology and clinical 
behavior. There are geographical and racial variations in incidence. In Japan and 
Asiatic women clear cell ovarian cancer is encountered in more than 11% of the cases, 
whereas in Caucasian women only in 5%. (14). Clear cell carcinoma is mostly being 
diagnosed at early stages, when disease is confined only to the ovaries. Between the 
most encountered genomic alterations there are ARID1A and PIK3CA (2). In some 
cases p53, PTEN, Kras mutations can be encountered.  
  
Mucinous ovarian cancer represents a small and very distinct subset of ovarian 
carcinomas (15). Most of the tumors are benign or borderline tumors of the ovaries. 
There are usually diagnosed in FIGO stage I, when disease remained confined to the 
ovary. Therefore they have a good prognosis following surgery, with the 5-year 
disease-free survival of 90.8%, compared with serous cancer of the ovary, 75.9% (16). 
There is a high frequency of intestinal differentiation in BOT (borderline tumors) and 
in malignant mucinous tumors of the ovary, which are also observed in metastatic 
gastrointestinal neoplasms. Due to this similarity many scientists suspect that actually 
mucinous ovarian cancers are metastatic tumors of the gastrointestinal tract. The 
majority of mucinous malignancies that metastasize to the ovary are having their origin 
in gastrointestinal tract, pancreas, cervix, breast, and uterus (15). Therefore in case of 
mucinous ovarian cancer, an appendectomy together with gastroscopy and coloscopy 
are mandatory for the differential diagnosis. There is overall accepted consensus that 
true mucinous malignant tumors of the ovary are rare. They seem to come from 
mucinous borderline tumors and teratomas (17). Few are known about their 
biomolecular characteristics. KRAS, RNF4, ERBB2 and p53 mutations are known so 
far (17, 18). KRAS mutations are found in approximately 43% to 57% of 
mucinous tumors (17, 18). The genetic data suggest that the origin of these tumors is 
in the benign mucinous cystadenoma that will progress to mucinous borderline tumor 
of the ovary, before the onset of the invasive disease. This is suggested by the highly 
incidence of ras mutations in mucinous LMP tumors and adenocarcinoma. Mutations 
in bRAF and Kras are usually observed in serous borderline but they are not 
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1.1.2 Etiology and molecular biology of borderline tumors of the ovary 
(BOT) 
Borderline tumors of the ovary are a distinct entity of ovarian tumors, having a very 
good prognosis and being usually diagnosed in younger patients (20). They are 
characterized by complex papillary architecture, multilayed epithelium with tufting, 
mild nuclear atypia, and slightly increased mitotic activity, without destructive stromal 
invasion (20).  
Borderline tumors have a longer clinical history, although their diagnosis is very 
difficult, BOT mimicking both malignant and benign sonographic features (21).  
In 2014, the new WHO classification differentiated between BOT with and without 
invasive implants. The last of them being classified as low grade ovarian cancer (22). 
This new classification took into account the last pathogenesis theory of ovarian 
cancer.  
Serous borderline tumors of the ovary are rarely associated with serous invasive 
epithelial carcinoma, therefore BOT are probably a different entity. Nevertheless in 
some cases serous BOT will progress to carcinoma, therefore some relation might 
exist. In the contrary mucinous BOT are often associated with mucinous EOC. So some 
BOT are precursors of EOC, some of them not (23).  
Sequence mutations in KRAS, BRAF and ERBB2 oncogenes are often seen in BOT 
(23). Mutations in these genes are encountered in about 2/3 of serous BOT, but are 
almost not met in HGSOC (23). Mutations in p53 are extraordinary in BOT.  
There are hints that BOT will progress into a non-invasive low grade carcinoma and 
afterwards in an invasive low-grade carcinoma, but there are no relations with HGSOC 
(23).  
The link between mucinous invasive ovarian cancer and mucinous BOT was suggested 
by clinical and pathological observations. Mucinous carcinomas are associated at time 
of diagnosis with area of mucinous BOT and of mucinous cystadenoma. Furthermore, 
point mutations of KRAS gene were observed in mucinous cystadenoma, BOT and 
EOC lesions (23).  
 
1.2 Hereditary ovarian cancer  
 
BRCA1 and BRCA2 were identified in 1990s as genes, associated with high risk for 
breast, epithelial ovarian, fallopian tube, primary peritoneal and other cancers, when 
mutated (24). These findings strength the idea of hereditary ovarian cancer, that is 
associated by younger ages, late stages, good response to platinum base chemotherapy 
and long disease evolution. Further studies documented that the incidence of hereditary 
ovarian cancer lies between 5% to 15%, depending on the population evaluated. 
Mutations in BRCA1/2 and mismatch repair genes of Lynch syndrome are mostly 
responsible for the hereditary ovarian cancers, although most of ovarian cancer cases 
are sporadic in origin (24). 
Primary ovarian cancer treatment consist platinum based chemotherapy. These 
compounds exert an anti-tumor effect by inducing intra-strand and inter-strand 
crosslinks in genomic DNA (25). The Cancer Genome Atlas analysis showed that 
somatic inactivation of BRCA1 and 2 genes through mutations and epigenetic changes 
(9). The presence of inactivating mutations in BRCA1 and BRCA2 genes, are making 
the ovarian cancer cells more sensitive to the DNA-damaging effects of platinum 
compounds. Furthermore data generated by the cancer genome study showed other 
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genetic mutations of homologous recombination genes, e.g. BR1P1, RAD51C, 
RAD51D, EMSY, PTEN, ATM, ATR, and Fanconi anemia that combined with 
BRCA1 and BRCA2 mutations affect approx. 50% of HGSOC patients (9). 
The presence of HRD has not only have an impact on genetic counseling, or screening 
strategies, but also on the development of new targeted therapies. In BRCA-deficient 
tumors the defect in homologous recombination can be replaced by the PARP pathway, 
on which base excision repairs relies on (24). If the pathway is blocked via PARP 
inhibition, the loss of both repair mechanisms leads to accumulation of DNA breaks 
and, ultimately, cell death (24).  




1.3 Ovarian cancer diagnosis 
 
Ovarian cancer is called “silent killer”, and has no specific symptoms in early stages 
(26). Most of the patients present themselves first with increase in abdominal volume 
due to ascites and diffuse peritoneal carcinomatosis.  
Serological tests, including the classical biomarkers, (eg. Ca125 and HE4) and 
imagistic analysis are the two pillars of the early diagnosis (27-29). From all imagistic 
examinations, the most reliable and useful in the clinic is the one of transvaginal 
ultrasound. 
There were several attempts to develop an efficient screening test. The largest study 
was driven by UK researchers. Hereby over 200.000 postmenopausal women were 
enrolled. The patients were randomized in three groups: the control group (100.000 
women), here no action has been taken; the multimodal screening group (50.000 
postmenopausal women) and the ultrasound group (50.000 women). In the multimodal 
screening group annual CA125 was determined, CA125 velocity was compared and 
patients were divided into high-, intermediary- or low-risk using the ROCA (risk of 
ovarian cancer) algorithm (30). CA125 velocity was interpreted using the ROCA 
algorithm that compares each individuals CA125 profile to the pattern in ovarian 
cancer and benign diseases. The closer the profile is to known cases of ovarian cancer, 
the greater the risk for cancer. Based on that the algorithm calculates the percentage 
risk of having ovarian cancer (31).  
High-risk patients, according to ROCA algorithm received a transvaginal ultrasound 
by an expert ultrasound examiner, as a second stage screening test and then the decision 
regarding therapy was taken (30). Patients in ultrasound group were examined by 
transvaginal ultrasound yearly (32). At the annual screen, women with: normal risk of 
ovarian cancer (ROC), did return to annual screening; intermediate ROC, did repeat 
the CA-125 in 12 weeks; and with elevated ROC, did repeat CA-125 and transvaginal 
ultrasound in 6 weeks, or even earlier if results were suggestive of clinical disease (30).  
 
The preliminary results published in 2009 showed that in the ultrasound group 845 
surgeries were performed due to suspect adnexal masses, whereas only 22 patients had 
an ovarian cancer or a borderline tumor. In the multimodal screening group 97 
surgeries were performed, 2.9 surgeries per diagnosed ovarian cancer. These results 
are translated in a better sensitivity (89.5%) and specificity (99.8%) for the multimodal 
screening group compared to the ultrasound group (75% and 98.2%, respectively). 
Both arms diagnosed 47.1% and 50% early stage ovarian cancer, respectively (FIGO 
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stage I and II), significant more than what we know from the literature. Until now there 
are no data from the control group, and therefore no information about impact of 
screening on survival rates (32).  
The analysis of serial CA125 testing compared with single-threshold (30), ROCA 
detected 86.4% of the 155 women with invasive epithelial ovarian cancers: in the 
meanwhile using only the annual serum CA-125 cutoff values of more than 35, more 
than 30, and more than 22 U/mL would have identified only 41.3%, 48.4%, and 66.5%, 
respectively (30). 
The main aim of the study was to show an advantage in overall survival, therefore there 
are still no efficient screening tests for ovarian cancer. Nevertheless the study shows a 
more important clinical value of CA125 velocity as a single-threshold rule for CA-125.  
Further attempts have been made in order to increase the number of cases being 
diagnosed in early stages. The so called gold-standard biomarker for ovarian cancer, 
the CA125 is a protein being overexpressed in around 80% of ovarian cancer cases, 
but unfortunately only in 50% of the early cases. Furthermore around 20% of ovarian 
cancer patients have a normal CA125 (33). Therefore CA125 has a limited value for 
the early diagnosis. CA125 is elevated in several malignancies but also in benign 
conditions, such as myoma, pregnancy, benign ovarian cysts, endometriosis. Since 
many years researchers are trying to discover biomarkers that can compete with 
CA125. The first serum biomarker that could compete with CA125 was human 
epididymal protein 4, a protein being first discovered in the human epidiydimal 
epithelium (34). Similar to CA125, HE4 is overexpressed in serous and endometrioid 
ovarian cancer patients (34). Elevated HE4 serum levels are present not only in ovarian 
cancer, but also in endometrium, gastric and non-small cell lung cancer (35, 36, 37). 
There are data suggesting promotive effects of the HE4 on gastric cancer, 
endometrial and ovarian cancer (35, 38, 39).  
Recent data showed that CA125 is more often elevated within benign ovarian disease, 
as HE4, especially in endometriosis, making HE4 the preferred biomarker to assess the 
risk for ovarian cancer in premenopausal pelvic mass patients (40).  Both HE4 and 
CA125 values are elevated in renal and hepatic failure, their value being limited within 
these cases (41).  
 
1.4 Surgical treatment in ovarian cancer 
 
Although ovarian cancer is diagnosed in advanced stage, maximal tumor debulking 
can be achieved in around 70% of the patients. Several studies showed the key role of 
optimal tumor debulking, in terms of no evidence of macroscopically residuals. 
Optimal primary debulking is associated with a significant benefit in both OS and PFS 
(42, 43). A metaanalysis of Bristow et al. showed that a decrease of 10% in the residual 
tumor mass, was associated with an increase of 5.5% of median overall survival (43). 
The primary cytoreduction of ovarian cancer requires multiple visceral surgery, that 
can be performed by trained gynecological oncologists. Reported data showed that 
patients operated in high volume centers, will have less peri- and postoperative 
complications and optimal residual mass can be achieved more often (44-46), those 
increasing the survival rates in ovarian cancer patients.  
Despite improvement in surgical techniques, there are still patients in whom optimal 
tumor debulkingcannot be achieved. These patients will usually relapse and will 
develop platinum refractory or resistant disease with early recurrence. Furthermore 
tumor debulking in ovarian cancer patients consists in a multivisceral surgery, 
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including bowel, diaphragm resection, peritonectomy and splenectomy (47, 48). By 
now there are no available predictive biomarkers for surgical outcome.  
There are still contradictory results if interval debulking (IDS) or primary debulking 
surgery (PDS) is the treatment of choice in advanced primary ovarian cancer patients. 
There are two prospective randomized clinical studies analyzing the role of 
neoadjuvant chemotherapy for ovarian cancer treatment (49-51). Vergote et al. showed 
in 2010 that patients with advanced epithelial ovarian cancer (EOC) undergoing 
neoadjuvant chemotherapy, followed by interval debulking have similar overall- (HR 
for IDS 0.98 95%CI (0.85-1.14)) and progression free- survival rates (HR for IDS 0.99 
95%CI (0.87-1.13)) as patients undergoing primary debulking surgery, followed by 
chemotherapy (49). In the EORTC trial the largest residual tumor was 1cm or smaller 
in 41.6% of the patients in the PDS arm and 80% in the IDS arm, with a trend of more 
peri- and postoperative complications in the PDS arm. The 28-days surgical mortality 
was 2.5% vs. 0.7%, grade 3 or 4 hemorrhage were 7.4% vs. 4.1%, infection rates: 8.1% 
vs. 1.7% and venous complications 2.6% vs. 0% in PDS vs. IDS arm, respectively (49).  
The second randomized clinical study was performed in UK, the first data were 
presented at ASCO 2013 by Kehoe. The CHORUS trial randomly assigned 552 
patients, 550 being eligible for the study (50). The study showed similar results: similar 
PFS (HR=0.9, 95%CI (0.75, 1,07)) and OS (HR= 0.87, 95% CI (0.71, 1.05)) rates in 
IDS (median PFS= 11.7 months and median OS=24.5months) and PDS arm (median 
PFS=10.3 months, median OS=22.8 months). Even in this study, the rate of 
postoperative complications was significant lower in IDS compared to PDS arm: any 
grade ¾ complication rates were 2% in PDS vs. 14% in IDS arm. 74% of the patients 
were discharges within 14 days post-op in PDS vs. 92% of the patients in IDS arm.   
The major criticisms to both studies are the low resection rates achieved at primary 
tumor debulking, short duration of surgery and poor survival rates. Furthermore despite 
significant increase of total macroscopic tumor clearance from 16% to 40%  (50) there 
were no significant differences in OS and PFS rates.  
Therefore further randomized prospective clinical trials are needed in order to elucidate 
the role of IDS and PDS in advanced ovarian cancer patients. In the next year the 
randomized international multicentric study, TRUST-Study, analyzing the role of 
interval debulking vs. primary debulking surgery in advanced ovarian cancer patients 
will start patients’ recruitment.  
 
 
1.5 Systemic therapy in primary ovarian cancer 
 
The standard chemotherapy in primary ovarian cancer patients consists in a 
combination of carboplatin and paclitaxel for 6 cycles every three weeks (53).  
In early stages ovarian cancer, studies showed patients who undergone complete tumor 
debulking and adequate staging surgery might not benefit from systemic chemotherapy 
treatment (53). Nevertheless, the results from ICON1 showed that adjuvant cytotoxic 
chemotherapy should be considered in high-risk patients, defined as patients with 
HGSOC or clear cell histology, or presence of stage IC ovarian cancer (53, 54). 
Even though about 75% of the patients have clinical complete remission (cCR) after 
first-line treatment, most of them relapse and eventually die of cancer, indicating the 
need for further treatment improvements (8). Treatment resistance will eventually 
emerge in 80-90% of the patients initially diagnosed with widespread of the disease 
(8). Despite the fact that platinum response is the second most important prognostic 
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factor for ovarian cancer patients, there are no reliable predictive biomarkers for 
response to platinum based chemotherapy. The global standard of care remained 
carboplatin and paclitaxel within the last 20 years (53).  
The tumors need blood vessels to be able to grow and invade other spaces. Furthermore 
studies showed an increased expression in ovarian cancer tissue, blood and ascites 
samples (55). This observation gave birth to the idea to combine chemotherapy with 
antiangiogenic drugs in order to improve survival in primary EOC patients.  
There were two positive phase III studies in primary settings. The GOG-0218 and 
ICON 7 studies analyzed the role of adding bevacizumab, a VEGF inhibitor to the 
standard chemotherapy treatment. The GOG -0218 study showed a benefit in PFS for 
patients treated with carboplatin/paclitaxel and bevacizumab, 15mg per kilogram of 
body weight, followed by bevacizumab alone as maintenance therapy (HR=0.717 
(95% CI, 0.625 to 0.824; P<0.001) (56). In the ICON 7 study, adding bevacizumab, 
7.5mg per kilogram of body weight, to the first line chemotherapy and than continuing 
the therapy as maintenance regimen resulted in significant improved PFS (HR= 0.81; 
95% CI (0.70 to 0.94; P=0.004) (57). None of the studies showed an improved overall 
survival, mainly due to low number of events, and different chemotherapy regimens 
in the 2nd and 3rd line including angiogenic drugs.  
Both studies showed a benefit in the progression free survival but this wasn’t translated 
in improved overall survival (56, 57).   
At ASCO 2014, Gourley et al presented the results of the subanalysis performed in part 
of ICON7 samples. Using unsupervised hierarchical clustering, three major subgroups 
of patients: two with angiogenic gene upregulation (the proangiogenic groups) and one 
with angiogenic gene repression and immune gene upregulation (the immune 
molecular subgroup) were identified. The survival analysis showed a significant 
improvement in OS and PFS survival rates (p=0.001 for both) for the immune subgroup 
of patients. When this signature was evaluated within part of the ICON7 samples, in 
the control arm better PFS (HR 0.47, 95% CI 0.32, 0.71; p < 0.001) and OS (HR 0.45, 
95% CI 0.26, 0.79; p = 0.005) rates were observed in comparison with the pro-
angiogenic group. When looking into the bevacizumab arm, those patients in the 
immune subgroup had significantly worse PFS (p=0.015) when treated with 
bevacizumab and chemotherapy compared with chemotherapy alone. On the other 
hand patients in the pro-angiogenic group had a trend to improve survival when adding 
bevacizumab (PFS of 17.4 months) compared with chemotherapy alone (PFS of 12.3 
months) (58). These results are very important and of high clinical interest as they are 
defining patients subpopulation who might benefit from adding bevacizumab to the 
first line chemotherapy. Nevertheless, larger studies that confirm these results are 
needed.  
As stated before the high grade serous ovarian cancer is characterized by a high rate of 
p53 mutations and often deficient in homologous recombination and repair of double-
strand DNA breaks (9). This deficiency has led to promising new treatment 
approaches, both as single agent and in combination with cytotoxic or anti-angiogenic 
drugs (59).  
PARP inhibitors were mainly considered for high grade serous ovarian cancer patients 
with genomic BRCA1/2 mutations. The data from the TCGA publication, showing 
increase somatic mutation in homologous recombination genes, has led to 
reconsideration of that approach (9). The maintenance therapy with Olaparib, a potent 
PARP inhibitor showed, in platinum sensitive relapsed ovarian cancer patients, that 
patients with BRCA1 or 2 mutations benefit from such a therapeutically approach (60). 
These data support the hypothesis that tumors with a homologous recombination 
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deficiency, will respond to PARP inhibitors. Therefore studies assessing the role of 
Olaparib in primary ovarian cancer patients are ongoing (SOLO1- Olaparib 
Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following 
First Line Platinum Based Chemotherapy) (61).   
Recent work has showed that homologous recombination (HR) can be suppressed by 
hypoxia through downregulation of BRCA1 and RAD51; therefore sensitivity to PARP 
inhibition is increased in hypoxic states (62-65). Hence PARP-inhibitors and anti-
angiogenics may have synergistic effects. In a phase 2 clinical study in platinum 
sensitive ovarian cancer relapses, there was a significant increased median PFS in 44 
(17·7 months (95% CI 14·7-not reached)) women who received the combination of 
olapariband cediranib, vs  the PFS in 46 women who received olaparib alone (9·0 
months (95% CI 5·7-16·5)); reaching a HR of 0.42 (95% CI 0·23-0·76; p=0·005) (66).  
New strategies combining Bevacizumab and Olaparib in primary ovarian cancer 
patients (PAOLA 1study- Platine, Avastin and OLAparib in 1st Line) are on going 
(67). 
 
1.6 Clinical management of ovarian cancer relapse 
 
The therapeutic scenario for ovarian cancer relapse remains undefined. 
The role of cytoreductive surgery in relapse situation remains unclear. Data from 
prospective trials are missing. So far results from retrospective studies suggest that 
cancer patients who will be optimal debulked might benefit from such an approach (68, 
69). However until now the effective clinical or imagistic criteria to identify the 
collective of patients who might benefit from this approach are uncertain. The 
DESKTOP studies, analysed the role of secondary cytoreduction in ovarian cancer 
patients with first platinum sensitive relapse. The DESKTOP I trial showed in a 
retrospective study that cytoreduction impact the overall survival rates: 45 months vs. 
19 months in completely debulked patients vs. patients with incomplete resection of 
recurrent disease (68). In the multivariate analysis following factors were associated 
with maximal tumor reduction: absence of residual mass after primary cytoredcution, 
ECOG status and ascites volume smaller than 500ml.  
All these factors merged into the AGO score. The AGO Score was evaluated 
prospectively in a multicenter setting, in the DESKTOP II study (70). From 516 
patients with first or second platinum sensitive relapse 261 had a positive AGO score 
and 129 patients received a secondary tumor debulking.  The rate of complete resection 
in AGO score positive first relapsed patients was 76% (95% CI, 69%-83, meaning that 
in 2 of 3 relapsed ovarian cancer patients the results of the secondary debulking surgery 
could be predicted correctly (70). The results of the DESKTOP III prospective 
multicentric clinical trial are expected in order to understand the role of secondary 
debulking in EOC.  DESKTOP III trial is a randomized, prospective, international trials 
that analyze the role of secondary cytoreduction followed by chemotherapy vs. 
chemotherapy alone in platinum sensitive relapsed ovarian cancer patients.  More than 
400 patients with a positive AGO score (Performance status ECOG 0; no residual 
tumor after primary surgery (if unknown, alternatively primary FIGO stage I/II); 
absence of ascites (cut off < 500 ml: radiological or ultrasound estimation) have been 
randomized. The used chemotherapy was a platinum based regimen, but otherwise a 
physician choice treatment (71). This prospective randomized trial is designed to 
elucidate the role of surgery or chemotherapy treatment in platinum sensitive ovarian 
cancer relapse. 
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The therapeutic strategy is guided by the platinum response. In patients being platinum-
sensitive the therapeutic strategy is a re-challenge with carboplatin-based regimen. 
Usually the second line chemotherapy is a combination of Carboplatin and Pegylated 
liposomal Doxorubicin (PLD) or Gemcitabine, respectively. In the Phase III clinical 
trial Calypso, the combination of Carboplatin with PLD showed no inferiority in terms 
of overall survival rates, but better toxicity profile especially due to less neuropathy 
(72).   
 
Women with recurrent platinum-sensitive EOC were included in the phase III 
randomized OCEANS. Patients were randomized in carboplatin plus gemcitabine with 
or without bevacizumab for 10 cycles maximum, followed by bevacizumab alone until 
disease progression or toxicity. The results from this study showed an improved PFS 
in the study group (12 months with bevacizumab vs. 8 months in the placebo group; 
HR = 0.48; 95% CI, 0.39–0.61) with no improvement in overall survival rates (73).  
 
In a recent study, Ledermann et al investigated the efficacy of a specific PARP inhibitor 
in high grade serous ovarian cancer patients.131 patients with platinum sensitive EOC 
relapse were assigned to treatment with Olaparib, whereas 123 patients were included 
in the placebo group. Around 56% and 50% of the patients, respectively had deleterious 
or suspected deleterious germline or somatic BRCA mutations. In BRCA mutated 
patients, median PFS was significantly longer in the olaparib arm than in the placebo 
group (11.2 months vs. 4.3 months). The same trend was observed in BRCA wild-type 
patients although the difference was smaller (7.4 months vs. 5.5 months, respectively). 
There was no impact of PARP inhibition on the overall survival rates in the BRCA 
positive or negative patients (60).  
 
Current data showed that the combination of antiangiogenic therapy (Cediranib) and 
PARP inhibitor (Olaparib) have a synergistic effect in recurrent platinum sensitive 
ovarian cancer patients with a 58% reduced risk of disease progression in the 
combination arm (66). 
 
Knowing that at least 50% of HGSOC may have homologous recombination 
deficiency, the response to PARP inhibition is expected to be present even in BRCAwt 
HRD tumors. ARIEL2, prospectively tested a novel next generation sequencing-based 
HRD assay and algorithm to predict the response to Rucaparib, a PARP inhibitor. Two 
hundred six platinum sensitive ovarian cancer patients have been included into the 
studies. The preliminary results suggested that HRD HGSOC tumors together with 
BRCA positive tumors are more likely to respond to PARP inhibitors (74).  
 
For platinum resistant ovarian cancer there is no efficient strategy of treatment and 
systemic treatment is highly dependent on the physician’s choice. In platinum 
resistance setting the prognosis is very poor. In the clinical setting single agent 
treatment with non-pegylated or pegylated liposomal Doxorubicin (PLD), Topotecan, 
Gemcitabine and alkylating agents such as Treosulphan or Cyclophosphamide are 
used, but they have shown a relative modest anti-tumor activity. This is reflected by 
low response rates less than 20% for each agent and short lasting remissions (75, 76). 
Paclitaxel weekly at a dose of 80-90 mg/m2/week, seems to be one of the most effective 
regimen in that situation yielding response rates in the range of 20-60% (77).  
Even in platinum resistant setting bevacizumab improved survival in combination with 
monotherapy, followed by bevacizumab alone as maintenance treatment. The 
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AURELIA Study analyzed the role of adding Bevacizumab to standard monotherapy 
in platinum resistant EOC relapsed patients. The PFS hazard ration was 0.48 (95%CI 
0.38 to 0.60), in the favor of Bevacizumab treated patients with 3.3 months longer PFS  
compared with chemotherapy treatment  alone. No statistical significant benefit was 




According to current guidelines, patients should address to gynecologists for clinical 
examination and ultrasound every 3 months within the first three years, followed by 
every 6 months between three and five years, and once yearly after the first five years. 
Recurrence can be detected in several ways: using the gynecological examination and 
ultrasound (local relapse or ascites can be detected), clinical symptoms of the patients, 
using CT, MRI or using the CA125 values. According to GCIG criteria a doubling in 
CA125-concentration above the upper limit of normal might indicate relapse in ovarian 
cancer patients (79).  
The largest study addressing the value of CA125 for the follow up in ovarian cancer is 
the study by Gordon et al (80). They analyzed timing of second line chemotherapy 
according to the CA125 level. Therefore women who developed recurrent disease were 
randomized to receive chemotherapy on the basis of either recurrence detected by 
elevated Ca125 (according to GCIG criteria), or based on clinical symptoms or relapse 
detected by imaging. In the CA125 group 254 patients have been randomized and in 
the imaging group 233 patients, respectively. Primary aim of this study was the impact 
of early treatment on overall survival rates, secondary aims were the time to begin 2nd 
line and 3rd line chemotherapy together with quality of life. The results of the study 
showed that relapse was diagnosed 4.8 months earlier (HR=0.29 (95% CI 0.24, 0.35) 
p<0.00001) in the CA125 subgroup, but the early intervention due to rising CA125 
concentration did not improve survival (HR=1.00 (95%CI 0.82-1.22) p=0.98). Due to 
more chemotherapy regimens, patients who started an earlier treatment based on 
CA125 raising levels had poorer quality of life. The results are still controversial, due 
to the fact that a possible drawback of the study is that almost all patients received only 
adjuvant treatment, and the role of secondary or tertiary debulking was not addressed. 
Nevertheless until now there is no evidence on the role of debulking in ovarian cancer 
relapse.  Because of the palliative setting of relapse disease, further treatment should 
be initiated on the basis of radiological findings, the clinical features and should take 
into consideration the preferences of the patient and her oncologists, at least until the 
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2 Aim of the study 
 
Aims of the present research were: 
 
1. To analyze the diagnostic value of different biomarkers (e.g. HE4, CA125, 
glycanes) in healthy women and patients with pelvic masses, including 
borderline tumors of the ovary and epithelial ovarian cancer (EOC). 
2. To analyzed the role of biomarkers and tumor phenotype in predicting surgical 







































  16 
3 Personal contribution 
 
3.1 Prognostic biomarkers for risk assessment in patients with pelvic mass 
 
3.1.1 Role of HE4 in the diagnosis of borderline tumors of the ovary 
 
Preoperative HE4 and risk of ovarian malignancy algorithm (ROMA) values do not 
improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a 
study of the TOC Consortium  
Elena Ioana Braicu, Toon Van Gorp, Mani Nassir, Rolf Richter, Radoslav Chekerov, 
Khayal Gasimli, Dirk Timmerman, Ignace Vergote, Jalid Sehouli. Journal of Ovarian 
Research 2014, 7:49.  
 
Borderline tumors (BOT) of the ovary are different from malignant or benign epithelial 
ovarian tumors. They are characterized usually by diagnosis in younger patients, very 
long clinical history and have usually a very good prognosis (81, 82). From the 
histological point of view, BOT are characterized by the presence of nuclear atypia 
without any destructive stromal invasion (81, 82). They can still present microinvasion, 
lymph nodes involvement as also peritoneal implants. The peritoneal implants might 
be non-invasive or invasive, in the last case they are classified, according to the new 
WHO classification as low grade serous ovarian cancer (22).  
BOT are usually diagnosed in early stages and chemotherapy is not indicated (85). The 
standard of care for BOT consists in bilateral oophorectomy, subtotal omentectomy 
together with comprehensive staging, including peritoneal biopsies, removal of all 
macroscopic peritoneal implants and peritoneal washings (83, 86, 87). Despite good 
prognosis, 10 to 30% of the patients will recur and 30% of them will develop an ovarian 
cancer (20).  
BOT is difficult to assess preoperatively. The ultrasound features are overlapping with 
both invasive and benign ovarian masses. Before surgery only 29-69% of the BOT are 
classified correctly (21). Until now predicting BOT using CA125 values in pelvic mass 
patients is controversial discussed. The aim of this study was to analyze the role of 
HE4 in predicting presence of BOT in pelvic mass patients.  
 
Therefore preoperative serum values were analyzed for both CA125 and HE4 in 167 
women with BOT or benign diseases. Overall 63 patients were diagnosed with BOT, 
whereas 15 patients were presenting invasive implants at the time of diagnosis.  
 
Due to the fact that BOT and benign diseases have different incidence within pre- and 
postmenopausal patients, the role of HE4 and CA125 was analyzed separately for pre- 
and postmenopausal patients. In the premenopausal collective of patients both HE4 
(p=0.984) and CA125 (p=0.141) showed no statistical significant differences between 
benign disease, BOT with and without invasive implants.  
Within the postmenopausal patients both biomarkers, HE4 (p=0.007) and CA125 
(p=0.003) differed significantly between benign diseases, BOT independent from the 
presence of invasive implants. HE4 and CA125 reached an area under the curve (AUC) 
of 0.732 and 0.778, respectively. The ROMA algorithm, consisting in the combination 
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of both biomarkers together with menopausal status reached a slightly improved AUC 
of 0.782, compared with biomarkers alone.  
Due to differences in median age within the three subgroups we performed the analysis 
in matched paired samples. Even in this sub-analysis the performance of HE4, CA125 
and ROMA remained poor for the diagnosis of BOT or detection of invasive implants 
(AUC=0.660, AUC=0.788 and AUC=0.744, respectively).  
Our study showed that HE4 alone did not perform better than CA125, alone in 
predicting the presence of BOT. Furthermore the combination of both biomarkers 
within ROMA algorithm cannot outperform the prognosis of CA125.  
 
These results underline once more the fact that BOT are a different entity compared to 
ovarian cancer and new biomarkers or early diagnosis algorithms should be developed 
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3.1.2 The serum glycome to discriminate between early stage epithelial 
ovarian cancer and benign ovarian diseases 
Karina Biskup, Elena Ioana Braicu, Jalid Sehouli, Rudolf Tauber, Véronique 
Blanchard. Dis Markers. 2014;2014:238197. 
 
 
In a further study we try to identify a new strategy for early detection of ovarian cancer. 
As mentioned above, until now there are no reliable biomarkers or clinical parameters 
to screen or diagnose ovarian cancer in early stages.  
 
Glycosylation is post-translational modification of the proteins, having an important 
impact in their function. Furthermore, glycome modulations were described in 
different diseases, including inflammation and cancer (88-90). Therefore glycane  
profile in serum was studied for diagnostic, monitoring and prognostic purposes. 
Increase in serum fucosylation, antennarity, and sialysation was reported in 
inflammation and in malignomas (91-95). Recent data showed that changing in N-
glycanes are cancer specific (91).  
 
In a previous study we analyzed 63 patients with mostly advanced EOC. Based on the 
analysis of gylcosilation profile, we defined a new diagnostic tool, GLYCOV, 
composed of the relative areas of the 11 N-glycan biomarkers, more specific four high-
mannose and seven complex-type fucosylated N-glycans (92). The sensitivity of 
GLYCOV score and CA125 were both 97%, the specificity was higher though for 
GLYCOV compared with CA125 (98.4% vs. 88.9%, respectively) (92).  
Due to the fact that the limitation of CA125 in the diagnosis of ovarian cancer is 
represented by its overexpression in only 50% of the early cases, we designed a new 
study, where we compared the diagnosis value of CA125 and GLYCOV score, within 
patients with early EOC (FIGO stage I 10 patients, FIGO stage II 10 patients). 20 
patients being diagnosed with different benign diseases and 33 age-matched healthy 
patients were included in the control group. N-Glycans were cleaved from serum 
glycoproteins, permethylated and analyzed using MALDI-TOF mass spectrometry.  
The predictive value of GLYCOV within patients with early EOC and healthy patients 
was analyzed using ROC. The AUC for GLYCOV was with 0.992 superior to that of 
CA125 (0.884), when analyzing cancer vs. control group. When comparing the early 
EOC and benign ovarian diseases the GLYCOV score (AUC=0.970) performed better 
than CA125  (AUC=0.680). This last comparison is of particular clinical relevance, as 
pelvic mass patients are usually the ones where differential diagnosis should be done.  
Our study showed a better sensitivity (95% vs. 60%) and specificity (80% vs. 65%) for 
the GLYCOV score than for CA125, respectively.  
The combination of both GLYCOV score and CA125 didn’t increase significantly the 
sensitivity and specificity of GLYCOV alone. Further prospective and multicentric 
studies are needed to validate these results. Furthermore the comparison between 
GLYCOV, HE4, ROMA and also with ultrasound features should be taken into 
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3.2 Predictive and prognostic role of somatic BRCA1 methylation status in 
ovarian cancer patients 
Ilary Ruscito, Desislava Dimitrova, Ines Vasconcelos, K. Gellhaus, T. Schwachula, F. 
Bellati, Robert Zeillinger, Pierluigi Benedetti-Panici, Ignace Vergote, Sven Mahner, 
Dan Cacsire-Tong, Nicole Concin, Silvia Darb-Esfahani, Sandrina Lambrechts, Jalid 
Sehouli, Sven Olek, Elena Ioana Braicu. Eur J Cancer. 2014 Aug;50(12):2090-8. 
 
High grade serous ovarian cancer is the most common and aggressive form of EOC. 
Although only 5 to 10% of ovarian cancer is hereditary and mostly linked to 
inactivation of BRCA1 and BRCA2 genes, the Cancer Genome Atlas publication 
showed that in fresh frozen tissue samples from HGSOC patients, functional loss of 
proteins involved in the homologous recombination pathway of DNA repair might be 
present in up to 50% (9).  
In order to improve survival rates in HGSOC patients, new therapeutic targets should 
be exploited. Therefor there is an increased effort in studying new therapeutic drugs 
and molecular mechanisms that interfere with deficient homologous recombination 
pathway. Hypermethylation of CpG island regions of specific oncosupressor gene 
promoters was identified as a new epigenetic phenomenon involved in the inhibition 
of tumor suppression and promotion of carcinogenesis (96, 97).  
 
The aim of this study was to analyze the clinical impact of BRCA1 promoter gene 
methylation status in HGSOC.  
Therefore 257 patients with primary HGSOC were enrolled consecutively. Tissue was 
provided by the tumor bank ovarian cancer (www.TOC-network.de) (207 patients) and 
from the European OVCAD consortium (50 patients).  
Written informed consent was obtained from all participant patients, before tissue 
samples have been collected. Approval from local ethic committees was provided 
(EK207/2003, ML2524, HEK190504, EK366 and EK260). 
Tissue samples were frozen immediately after removal during surgery in the liquid 
nitrogen. Before methylation analysis, samples underwent a central histological 
review, whereas the quality of the tumoral tissue was assessed. Only specimens 
presenting at least 50% of tumor area were included in the BRCA1 promoter 
methylation status analysis. Using the bisulfite modification of DNA and methylation-
specific PCR we assessed the methylation status of BRCA1 promoter gene.  
Median age at diagnosis was 58 years, over 94% of the patients had an advanced 
HGSOC (FIGO stage III and IV) and optimal debulking, in terms of no 
macroscopically tumor residuals, was obtained in 63% of the cases. All patients 
received primary tumor debulking followed by platinum based chemotherapy.  
In our study we included a heterogeneous population with a wide range of BRCA1 
promoter gene methylation rate.  Around 14.8% (34 patients) presented at least 5% of 
methylation in BRCA1 promoter gene, and were therefore called hypermethylated. 
Samples were obtained from different anatomic sites. Although no paired samples were 
available from same patients, no differences in methylation rates in samples originating 
from different anatomic sites were observed (p=0.83). No significant correlation 
between methylation status and residual tumor mass after surgery (p=0.585) or 
response to platinum based chemotherapy (p=0.14) was detected.  
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In the hypermethylated subgroup, patients were significantly younger (median age 54 
years) compared with patients in the hypomethylated group (median age 60 years) 
(p=0.008).  
There was no statistically significant impact of BRCA1 methylation status on survival 
rates (p=0.566 for PFS and p=0.109 for OS, respectively).   
In conclusion only age at first diagnosis was associated with BRCA1 promoter 
methylation status in our study. Therefore our results suggest that ovarian cancers 
associated with BRCA1 promoter hypermethylation are more likely to be diagnosed in 
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3.3 Predictive biomarkers for surgical outcome 
 
The crucial role of primary debulking surgery resulting in no macroscopic residual 
disease is already accepted worldwide. The role of neoadjuvant chemotherapy 
followed by interval debulking is not clear yet. Although there might be a 
subpopulation who will benefit from this approach:  
 In patients with a combination of risk factors such as: increased age, low 
performance status; comorbidities; cachexia/low albumin, enable to undergo 
extensive cytoreduction with large fluid shifts.  
 Emergency surgery in suboptimal setting  
 Fresh thromboembolic or cardiovascular event 
 Presence of diffuse unresectable intraparechymatous liver / lung metastases 
 Presence of diffuse miliary peritoneal carcinosis 
 Brain/Bone metastases 
 Suboptimal health ressources, such as intensive care units, blood bank 
availability etc.  
 
In relapse situation due to the lack of prospective data, there are still controversial 
opinions regarding the role of debulking surgery. Nevertheless data from retrospective 
studies are showing a benefit for patients undergoing optimal secondary, tertiary or 
quaternary surgery (68, 69, 98-101).  
Nevertheless, until now there are no predictive biomarkers or no reliable clinical 
parameters to preselect patients who would benefit from debulking surgery in primary 
or relapse setting.  
 
 
3.3.1 Role of histological type on surgical outcome and survival 
following radical primary tumor debulking of epithelial ovarian, 
fallopian tube and peritoneal cancers 
Elena Ioana Braicu, Jalid Sehouli, Rolf Richter, Klaus Pietzner, Carsten Denkert, 
Christina Fotopoulou. British Journal of Cancer (2011) 105, 1818-1824 
 
The aim of this study was to analyze in a large cohort of EOC patients, the clinical 
impact, in terms of influence on surgical outcome and survival rates, of the 2-tier 
system proposed by Kurman and Shih in 2004 (101). The so called type I tumors, 
having as prototype the low grade serous EOC, generally behave in an indolent manner, 
are genetically stable and tend to be diagnosed in early stages. The type II tumors of 
the ovary, having as prototype the HGSOC, are very aggressive, p53 mutations being 
present in more than 95% of the cases and are characterized by impaired homologous 
recombination. They are usually diagnosed in advanced stages and prognosis is very 
poor (10, 101).  
We enrolled retrospectively 632 patients, whereas 100 patients (15.8%) were classified 
as type I and 532 patients (84.1%) as type II tumors. Forty-four type I tumors (44%) 
were diagnosed in early stages. Type I patients were significantly younger, were 
diagnosed at earlier FIGO stages and had lower rates of preoperative ascites, positive 
lymph nodes and CA125 values.  
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Estimated 5-year and 2-year OS rates were 56.3%  and 59.8% for type I patients vs. 
39.3% and 44.9% for type II patients (p=0.021), respectively. Nevertheless, when 
considering only advanced FIGO IIIC/IV patients, both OS (p=0.779) and PFS 
(p=0.714) were similar between the histological sub-types. Platinum response also 
didn’t significantly differ within the two subgroups of patients (p=0.314).  
Regarding the surgical procedures, in type I patients dissection of para-aortic lymph 
nodes, extensive peritonectomy, diaphragm stripping and large bowel resection have 
been performed less frequent as in type II. A lower overall complication rate and a 
significantly shorter operative time was observed in type I patients. When only 
advanced stages were analyzed, there were no statistical significant differences 
regarding surgical procedures or postoperative complications. Complete tumor 
resection was significantly more often achieved in type I (85%) compared to type II 
tumors (65.6%) (p=0.001).  
The multivariate analysis identified postoperative tumor residuals, mucinous histology 
and presence of positive lymph nodes as independent predictors of survival. When the 
analysis was performed only in optimally debulked patients, presence of HGSOC, type 
II histology and multifocal tumor disseminations were negatively affecting the survival 
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3.3.2 Primary versus secondary cytoreduction for epithelial ovarian 
cancer: A paired analysis of tumour pattern and surgical 
outcome.  
Elena Ioana Braicu, Jalid Sehouli, Rolf Richter, Klaus Pietzner, Werner Lichtenegger, 
Christina Fotopoulou. European Journal of Cancer 48 (2012) 687-694.  
 
 
Although lately a more radical surgical approach is often usedleading to an increased 
number of optimal resected EOC patients (42, 43), most of patients will relapse, 
resulting in platinum resistance and consequently leading to death. Personalized 
therapy attempts failed in improving overall survival rates in EOC (8). Clinical 
observations regarding treatment failure may understand better temporal heterogeneity 
and progression of the disease leading to more effective strategies against it (103).  
The role of surgery in primary setting is with no doubt crucial for the prolongation of 
progression free and overall survival. The meaning of surgery in the relapse situation 
is still unclear. In the last decades, extensive data about the role of primary surgery, 
platinum based chemotherapy, as also data regarding mutations, epigenetic changes, 
copy number variations, gene expression of primary EOC have been generated. 
Nevertheless there are few patients receiving secondary or tertiary cytoreductive 
surgery, and therefore also few samples collected at disease relapse (8). Even more 
difficult is to find patients with well-documented, primary and secondary debulking 
and also patients where paired samples are available.   
Understanding the dissemination pattern and temporal tumor heterogeneity will bring 
more information about the evolution of ovarian cancer and resistant tumoral clones. 
Therefore we analyzed the role of tumor dissemination pattern in patients with both 
primary and recurrent disease with the aim of better understanding of tumor behavior 
and operative outcome in EOC patients. Therefore we included only patients being 
operated at both primary and relapse situation. 
We analyzed the clinical data from 79 patients operated in our center. All data were 
documented prospectively within our tumor bank for ovarian cancer (www.toc-
network.de). The tumor spread, maximal tumor load and residual tumor mass were 
documented during and at the end of the surgery through an interview with the surgeon 
and using a validated documentation tool, the intraoperative mapping of ovarian cancer 
(IMO) (104). Median overall survival and progression free survival to first relapse were 
56 months and 16 months, respectively. 
Patients developed less ascites in the relapse situation as prior to primary surgery 
(40.5% vs. 65.3%, p=0.002). In relapse situation patients had higher rates of tumor 
involvement of the gastric serosa (p=0.003), serosa of small intestine (p=0.001) and 
mesentery (p=0.012). Regarding surgical procedures: upper abdomen surgery was 
more frequent used during secondary debulking.  
Surgical effort resulted in significant higher maximal tumor debulking rates in primary 
situation compared to relapse (77% vs. 50%, p<0.001), at similar operative morbidity 
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(25% vs. 29%; p=0.424). The secondary cytoreduction was associated with 
significantly higher rates of tumor residuals in the abdominal levels 1 (p=0.008) and 
level 2 (p=0.001). Maximal tumor load affected mostly level 1 in primary setting 
(p=0.002) and level 3 at relapse (p=0.045). The residual tumor mass at primary and 
secondary cytoreduction correlated significantly (p=0.003). The relative risk of any 
residual tumor mass after secondary debulking was 1.91 in patients with sub-optimal 
primary debulking surgery versus patients who underwent complete macroscopically 
tumor resection at PDS.  
There was no correlation of tumor dissemination, in terms of peritoneal carcinomatosis, 
presence of positive lymph nodes and intestinal tumor involvement or at primary vs. 
secondary tumor debulking.  
Despite heavily pretreated patients, surgical morbidity at relapse doesn’t seem to 
increase significantly compared to primary setting when experienced surgeons perform 
surgery. Nevertheless maybe the temporal tumor heterogeneity leads to reappearance 
in a more aggressive and therapy resistant profile, which involves higher therapeutic 
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3.3.3 Role of HE4 in predicting surgical outcome 
 
3.3.3.1 Preoperative HE4 expression in plasma predicts surgical outcome in 
primary ovarian cancer patients. Results form the OVCAD study.  
Elena Ioana Braicu, Christina Fotopoulou, Toon Van Gorp, Rolf Richter, Radoslav 
Chekerov, Christina Hall, Hermann Butz, Dan Cacsire Castillo-Tong, Sven Mahner, 
Robert Zeillinger, Nicole Concin, Ignace Vergote, Jalid Sehouli. Gynecologic 
Oncology 128 (2013) 245-251.  
 
Human epididymal protein 4 was first identified in the epithelium of human 
epididymis. Further studies showed that it is overexpressed in epithelium of the 
respiratory and genitourinary tract (105). In 1999, Schummer et al, described for the 
first time HE4 being expressed in EOC (106).  
In 2008 Moore at al, analyzed the role of different biomarkers and their combination 
in predicting ovarian cancer in pelvic mass patients (38). In this study, the combination 
of CA125 and HE4 had the best AUC compared to any other biomarker alone, or any 
other biomarker combination (including triplets and quadruplets). Starting from this 
results and from the observation that most EOC occur in postmenopausal patients, as 
also that biomarkers serum concentrations are influenced by age, Moore proposed in a 
following study a new score for malignancy: the risk of ovarian malignancy algorithm 
(ROMA) (107). ROMA combines HE4 and CA125 together with menopausal status.  
Within the European OVCAD study we included 275 patients with primary epithelial 
ovarian cancer, who received debulking surgery and platinum based chemotherapy. 
Blood samples were available prior to surgery and in chemotherapy naïve patients 
(108).  
Aim of our study was to analyze the predictive value of HE4, for surgical outcome in 
primary EOC.  
Most of the patients (94.7%) were diagnosed in advanced FIGO stage (FIGO III and 
IV) and maximal tumor debulking was achieved in 68.4% of the cases. Over 86% of 
the patients had HGSOC.  
Median HE4 concentrations in plasma and in ascites were 339pM (interquartile range 
(IQR) 124pM-699pM) and 4339pM (IQR 2117pM-7552pM), respectively. Median 
value of circulatory CA125 was 456 IU/ml (IQR 123.7-1139.4).  
HE4 concentrations increased with advanced FIGO stage (p=0.004), increased ascites 
volume (p<0.001), presence of serous histological subtype (p=0.013) and high grade 
(p=0.034). Furthermore HE4 significantly correlated with CA125 levels (p<0.001).  
Both HE4 (AUC=0.635) and CA125 (AUC=0.643) correlated with residual tumor 
mass in the multivariate analysis. We identified following cut-off values 235pM and 
500pM, and 500IU/ml for HE4 and CA125, respectively as having the best sensitivity 
and specificity. Combining both biomarkers the sensitivity and specificity of predicting 
surgical outcome increased to 64.8% and 73.5%, respectively.  
In the multivariate analysis only CA125 (OR=3.8, 95% CI= 1.78-8.1) together with 
age (OR=3.33, 95%CI=1.2-9.14) were predictive for impaired surgical outcome. When 
adjusting after center, FIGO stage, ascites volume and histological subtype, HE4 
retained its statistical significance. This analysis lost its significance when adjusted 
after age.  
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We created a risk index, composed of HE4 (cut off value of 500pM) and CA125 (cut-
off value 500IU/ml). In the multivariate setting, this index was an independent 
predictive factor for surgical outcome (p<0.001).  
Furthermore both biomarkers correlated with platinum response (p=0.009 for HE4 and 
p=0.004 for CA125). None of the biomarkers were independent prognostic biomarkers 
for progression free or overall survival.  
 
The results of this study showed that CA125 and HE4, although associated with relative 
poor sensitivity and specificity might be used in predicting surgical outcome and in 
identifying patients who will benefit from primary debulking surgery. Nevertheless 
clinical parameters should be also taken into consideration in order to increase the 
sensitivity and specificity, eg. presence of ascites, ECOG status, age. Further more 
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3.3.3.2 HE4 Expression in plasma correlates with surgical outcome and overall 
survival in patients with first ovarian cancer relapse 
Elena Ioana Braicu, Radoslav Chekerov, Rolf Richter, Carmen Pop, Mani Nassir, 
Hanna Loefgren, Florin Stamatian, Mustafa Zelal Muallem, Christina Hall, Christina 
Fotopoulou, Jalid Sehouli, Klaus Pietzner. Ann Surg Oncol (2014) 21: 955-962 
 
If the role of surgical debulking is worldwide accepted for the primary situation, there 
is no enough evidence for the impact of debulking and of residual mass in the recurrent 
situation. There are retrospective data showing that patients might benefit from this 
strategy, if macroscopically tumor clearance can be achieved.  
Until now there are no validated biomarkers to preselect patients who will benefit from 
a secondary tumor debulking.  
In this study we analyzed the role of HE4 in predicting surgical and clinical outcome 
in relapsed ovarian cancer patients.  
We included 73 consecutive EOC patients with first relapse after primary debulking 
and platinum based chemotherapy. Optimal tumor debulking could be achieved in 
66.7% of all these patients and 86.3% were platinum sensitive.  
HE4 correlated with residual mass after secondary tumor debulking (AUC=0.731, 
p=0.001), and it retained its statistical significance even in the multivariate setting. 
CA125 did not reach the statistical significance (p=0.075).  
Combining HE4 and CA125 the AUC was slightly increased as when using HE4 alone 
(0.791 vs. 0.731). Furthermore, when performing the multivariate analysis for OS, HE4 
together with response to first platinum based chemotherapy were the only independent 
prognostic factors.  
Nevertheless the AUC reveal a poor sensitivity and specificity for both HE4 and 
CA125, indicating that there is a need to combine clinical features or characteristics 
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4 Discussion 
4.1 Prognostic biomarkers for risk assessment in patients with pelvic mass 
 
Despite increased aggressiveness in the surgical debulking and attempts of 
personalized medicine, ovarian cancer remains a deadly disease, with poor increase in 
survival rates in the last decades (8). This fact is mostly caused by diagnosis in 
advanced FIGO stages when survival rates are drastically decreased.  
For now on there are no diagnostic tools, no gene signature or biomarkers that can 
predict the risk of malignancy in the general or high-risk population or in the pelvic 
mass patients.  
Therefore there is an unmet need in identifying new diagnostic tools for early detection 
of ovarian cancer. Ideally these methods should be easy to reproduce and coast 
effective. Until now there are two different approaches: trying to triage the patients 
using biomarkers, usually in serum or using imagistic methods, here the transvaginal 
scan being widely used.   
Regarding the transvaginal scan, studies failed in showing a benefit mostly due to lack 
of standardized diagnostic procedure and due to method subjectivity. At the beginning 
of this century, the international study group for ovarian tumor analysis (IOTA) was 
founded. The IOTA group analyzed the role of transvaginal ultrasonography for the 
differential diagnosis of ovarian tumors. The first limitation of the transvaginal 
sonography was and still remains the lack of standardized terms and procedures to 
derive categorical and continuous variables in gynecological ultrasound (109). The first 
aim of the study group was to standardize the ultrasound examination (109).   
Discriminating between benign or malignant adnexal masses is the key point for an 
optimal clinical management. In most of the pelvic mass patients a benign tumor will 
be diagnosed (110). Different tools have been used in order to distinguish between 
benign or malignant adnexal masses, such as biomarkers and/or various prediction 
models (110). Scores based on morphological appearance of a mass during ultrasound; 
the risk of malignancy index (RMI): based on CA125, menopausal status and 
ultrasound characteristics, logistic regressions, neural networks and other 
computational approaches have been used in order to improve diagnosis (110, 111). 
The RMI remains the most widely used prediction model for pelvic mass patients, 
although is based on several ultrasound markers, without being standardized and 
CA125 (111). In the US, FDA approved CA125, HE4 and OVA1 for diagnostic 
purposes in pelvic mass patients (112). OVA1 is a tool that combines five biomarkers 
(CA 125, TTR, ApoA1, β-2 microglobulin, TF), which are identified through serum 
proteomics using SELDI-TOF-MS. Unfortunately the OVA1 has a high false positive 
results rate (112, 113), therefore its role in the clinical use is limited.  
Afterwards within the IOTA I study several logistic regression models have been 
analyzed. The LR1 included 12, and LR2 included six, demographic and ultrasound 
variables. These models were validated in an external cohort of patients. They 
compared the performance of the logarithmic regression models with the performance 
of RMI and CA125 using ROC analysis. The AUC of LR1was 0.945, LR2 0.922, RMI 
0.865 and of CA125 0.741, showing a better performance of IOTA logistic regressions. 
In the postmenopausal patients LR1 performed better than all other tests (LR2, RMI, 
and CA 125) (110). 
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Despite increase sensitivity and specificity of logarithmic regression models of IOTA 
group, the major limitation of ultrasound-based algorithm is the subjectivity of the 
analysis and the technical requirements. IOTA group developed the so called simple 
rules. These are a simplified version of ultrasound criteria and can predict the presence 
of malignancy in pelvic mass patients. They defined 5 malignant (M) criteria: presence 
of ascites, presence of more than 4 papillary projections, presence of moderate or 
strong blood flow, irregular solid tumors and irregular multilocular-solid lesions larger 
than 10cm; and 5 rules for benign (B) tumors: unilocular tumor or solid component 
smaller than 7mm, acoustic shadow, smooth multilocular lesions less than 10cm. 
Following clinical judgement applies: if only B rules apply, than the tumor mass is 
more likely benign; if only M rules apply than is malignant, if both B and M rules apply 
than the patient should be sent to an expert in pelvic ultrasound. Using these simple 
rules, the IOTA could correctly identify 81% of the benign diseases, 74% of the 
malignant tumors, but only 50% of the borderline tumors of the ovary (114). Another 
article published by Fisherova et al, showed that borderline tumors of the ovary are 
together with other benign tumors, the most difficult masses to correctly diagnose 
preoperatively, because their macroscopic features overlap with invasive and benign 
ovarian tumors (21).  
Despite worldwide use of ultrasound diagnostic, there are still difficulties in correctly 
identifying borderline tumors or early EOC. On the other hand the biomarkers are 
easily to be reproduced, are standardized and are usually cheaper than ultrasound or 
other imagistic techniques. Nevertheless the lack of effective biomarkers is currently a 
major obstacle for blood-based early detection in ovarian cancer (115). Hori et al, 
developed a mathematical model, to quantify the growing time required for a malignant 
tumor cell population to reach the minimal size so that it will be able to shed enough 
biomarker into the blood, so that biomarker levels could be detected using available 
clinical blood biomarker assays. The results showed only after 10.1 years the tumor 
will reach a volume corresponding to a spherical diameter of about 25.36 mm, and will 
consequently become detectable by current clinical blood assays and by transvaginal 
ultrasound (115). Therefore there is an urgent need to discover new diagnostic 
biomarkers for ovarian cancer. The mathematical models suggest a constant but slowly 
increase in biomarkers serum levels, suggesting that a biomarker single-threshold 
might not be that useful as its velocity. This hypothesis is also one of the main findings 
of the UKCTOCS screening trial (30). Therefore new strategies analyzing the role of 
biomarker velocity in pelvic mass patients should be developed.   
The HE4 is a new biomarker overexpressed in several epithelial tumors, but mostly in 
ovarian cancer. Since 2008 when the first study by Moore was published, there were 
many publications focusing on role of CA125 and HE4, or in combination (ROMA 
algorithm) to predict ovarian cancer in pelvic mass patients. The results obtained are 
rather contradictory. Moore et al showed that HE4 and ROMA performed better than 
CA125 alone or in any other biomarker combination (116). In a retrospective study by 
Van Gorp HE4 and ROMA did not increase the sensitivity and specificity of CA125 
alone, neither in pre- nor in postmenopausal patients (117). In a total of 360 pelvic 
mass patients, a retrospective analysis of different algorithms using ultrasound criteria 
or biomarkers showed that IOTA LR2 has a better diagnostic performance that ROMA 
for the characterization of pelvic masses (118). 
 
BOTs are correctly classified before surgery in few cases, only in 29%-69% (21), 
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therefore the aim of our study was to analyze the diagnostic role of HE4 alone or in 
combination with CA125. HE4 or ROMA did not perform better than CA125 in the 
diagnosis of BOT. Both CA125 and HE4 had low sensitivity and specificity for BOT, 
underlying once more that BOT are a different entity of ovarian tumors, and further 
biomarker discovery is needed. Using CA125 velocity doesn’t seem to improve the 
percentage of BOTs diagnosed correctly (30). No data are available regarding HE4 
velocity. The limitation of our study was the low number of BOT patients included and 
the lack of information regarding ultrasound features.  
Glycans are important for cell-cell adhesion, protein folding, host-pathogen 
interactions and cell signaling. Distinct differences between glycan profiles are seen 
between normal and cancer cells. Glycanes are suspected to be involved in cancer 
transformation and progression (119). A study carried out by our group on 96 subjects 
showed a modification of N-glycome of total serum glycoproteins in primary early-
stage and late-stage patients (92) using MALDI-TOF mass spectrometry. An increase 
of tri-, tetraantennary fucosylated and sialylated glycans was observed as well as a 
decrease of high-mannose N-glycans. The glycan structures that were significantly up- 
and downregulated were combined as a score named GLYCOV. GLYCOV was 
validated in this second cohort of patients including healthy donors, benign tumors of 
the ovary and early (FIGO I and II) EOC.  
Our findings were in concordance with previous published data that showed a 
downregulation of high-mannose structure in EOC patients (120, 121). Changes in N-
glycanes were present in 9 from 10 FIGO stage I and 10/10 FIGO stage II EOC, 
suggesting this is a process occurring early in the clinical history of EOC. Furthermore 
impairments in glycosylation haven’t been observed in almost none of benign cases.  
There are data suggesting that the regulation of high mannose content is probably 
linked to the C3 complement, which is the only acute phase protein that carries high 
mannose N glycans (122). The increase in monofucosylated triantennary trisialylated 
N-glycan was observed in several solid malignomas and in inflammatory conditions. 
The mechanism explaining aberrant glycan modulation in EOC patients might 
correlate with the production of acute phase proteins in the liver that are stimulated by 
different cytokines (e.g. TNF; IL 1 and IL6) (123-125). Here further studies are needed.   
Our study suggests that glycans, especially GLYCOV algorithm might be a potential 
early diagnostic score for EOC, having a better sensitivity and specificity than CA125. 
The limitation of the study is of course the relative low number of patients, the 
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4.2 Predictive and prognostic role of somatic BRCA1 methylation status in 
ovarian cancer patients 
 
Ovarian cancer is mostly sporadic but in 5 to 15% of the cases it is associated with 
positive family history. The so-called familial EOC is usually associated with 
mutations in homologous recombination genes, and here primary inactivation of 
BRCA1 and BRCA2 genes.  
High-grade serous ovarian cancer is the most common, but the most aggressive type of 
EOC. The analysis of 26 observational studies on ovarian cancer patients’ survival, on 
1213 EOC patients, showed that BRCA1/2 positive patients were having a survival 
benefit, especially in the BRCA2 positive subgroup (126). The improved overall 
survival rates in BRCA1/2 positive tumors is partly due to increased response to 
platinum based chemotherapy.  
Recently, the cancer genome study on more than 400 primary high-grade serous EOC 
patients, showed in up to 50% of the patients a functional loss of proteins involved in 
the homologous recombination pathway of DNA repair. Hence these tumors 
phenotypically behave similar to BRCA1/2 mutant cancers, even in the absence of a 
BRCA1/2 mutation. This higher percentage was achieved by analyzing not only the 
genomic DNA, but also the somatic mutations and epigenetic changes (9).  This 
phenomenon is called ‘BRCAness’ and defines DNA homologous recombination 
deficiency (127, 24).  
There are few data regarding the impact of epigenetic changes of BRCA1/2 genes in a 
homogenous HGSOC cohort. BRCA1 promoter methylation was reported in 5% to 
40% of the EOC, depending on analyzed cohort (128-133). Within the TCGA project 
BRCA1 gene promoter methylation was identified in 11.5% of the HGSOC. BRCA1 
and BRCA2 inactivation was the second most frequent alteration following the p53 
inactivation. Even in this study, the BRCA1/2 mutations was associated with a better 
overall survival due to higher sensitivity to DNA-damaging agents, especially 
platinum-compounds (9).  
Our study analyzed the role of methylation status in somatic BRCA1 promoter gene, 
in a homogenous cohort of HGSOC patients. This study was performed in a well 
clinical characterized cohort of patients. The largest limitation of the study was the lack 
of information regarding genomic and somatic mutations of BRCA1/2 genes. In 118 
patients we had available data with respect to mutation status in genomic BRCA1 exon 
11. Exon 11 represents 60% of the BRCA1 gene. In our study, 11 patients presented 
mutations by gene sequencing. None of the BRCA1 positive patients presented a 
second inactivation of the gene through methylation. These results were in 
concordance with those of the TCGA consortium. It seems that the inactivation of 
BRCA genes follows through mutations or through epigenetic changes, but the both 
mechanism are unusual to be seen together.  
In our study the incidence of BRCA1 promoter hypermethylation was of 14.8% , but 
there were no association with better PFS or OS rates, or with higher platinum response 
rates. Only age at first diagnosis was significant lower in hyper-methylated than in 
BRCA1 non-methylated patients. So our study strengthens once more that BRCA1 
positive tumors are diagnosed more often in younger patients. 
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These results were in concordance with previous published data. Cunnignham et al. 
showed that epigenetic alterations (hypermethylation) of BRCA1, and Rad51C genes 
were detected in 10.8% of the cases. The authors showed no differences in PFS and 
OS with respect to the BRCA1 promoter methylation status (134). In our study we 
described a slightly higher incidence of BRCA1 promoter methylation, which could be 
caused by inclusion only of HGSOC patients. Similar results were suggested by TCGA 
consortium, showing that epigenetically silenced BRCA1 had similar survival data 
with BRCA1 wild type HGSOC. No impact has been seen on the platinum sensitivity 
(9). Another study published by Yang et al, showed a positive prognostic effect on 
survival rates only in BRCA2 mutated tumors but not in BRCA1 mutated or 
hypermethylated tumors (135). In HGSOC patients, BRCA2 mutations but not BRCA1 
mutations or epigenetic changes are associated with improved platinum based 
chemotherapy response, improved survival and increased genome instability compared 
with BRCA wild-type tumors (135).  
Another recent study showed that the presence of BRCA1/2 mutations are translated 
in better short-term survival, but this advantage decreases over time, especially after 
4.8 years (the HR will become greater than 1, although 0.58 at time 0) and, in BRCA1 
carriers can be reversed. The combined 10-year overall survival for BRCA1/2 non-
carriers, BRCA1 and BRCA2 carriers was: 30% (95% CI, 28%-31%), 25% (95% CI, 
22%-28%), and 35% (95% CI, 30%-41%), respectively.  These finding might have 
important implications in the therapy of both primary and relapsed EOC. These results 
are also of clinical importance especially when considering the analysis of long-term 
survival in clinical trials with new agents, especially PARP inhibitors (136). This could 
be also explained by reversing frame-shift mutations in BRCA1 gene through 
secondary mutations, therefore developing platinum resistance (137-139).  This 
secondary mutations that might appear in the first, second or successive relapse are of 
major clinical interest, especially regarding the need of current biopsies before 
beginning of PARP inhibitors treatment.  
Our data suggest that younger ovarian cancer patients might present an epigenetic 
silencing of BRCA1 gene. Further studies identifying different mechanisms leading to 
HRD are warranted to tailor the oncologic treatment in HGSOC patients.  
In our working group we are planning to analyze the incidence of BRCAness in long 
term survivors, -patients with no relapse within the first 5 years after platinum based 
chemotherapy compared to patients who relapsed within the first 2 to 3 years. 
Moreover we would like to study the tumor heterogeneity, by analyzing the BRCAness 
in paired primary tumor and metastasis, as also in paired primary and recurrent HGSOC 






  89 
4.3 Predictive biomarkers for surgical outcome 
 
The corner stone of ovarian cancer treatment is surgery (45). Explorative laparotomy 
and histology are crucial for the staging of EOC. Especially in advanced cases, when 
the disease has spread throughout the peritoneal cavity, cytoreductive surgery is 
critical, and removing all macroscopic tumor masses results in better progression free 
and overall survival (42-46). Most of the patients are diagnosed in advanced stages. 
Therefore extensive multivisceral surgery is needed in the majority of the cases. In 
order to achieve high quality surgery, removal of the tumor should be performed 
without complications, or harm done to the patients (45). The absence of 
macroscopically tumor residuals is associated with optimal survival rates (45). Studies 
showed that surgical outcome in EOC is improved in high volume centers with large 
expertise in gynecological oncology. During tumor debulking often upper abdominal 
surgery is needed. Even in the hands of the best surgeons restrictions to the extent of 
surgery, and therefore suboptimal surgical outcome, might appear. This is mainly 
caused by tumor or patients related factors, such as tumor spread, invasion of vital 
organs or co-morbidities (45). There are no predictive biomarkers, clinical parameters 
or algorithms yet to be able to predict patients who will not benefit from primary 
cytoreductive surgery.  
Another unclear area is the role of tumor debulking for relapse situation. Prospective 
results from DESKTOP III clinical trial are expected. Until now data from 
retrospective studies, shows a benefit for optimal debulked patients undergoing 
secondary, tertiary and quaternary debulking (68, 69, 99, 101).  
The molecular biology of the tumor might play an important role even for surgical 
outcome. Ovarian cancer is not one disease, but many diseases under the same name. 
Different histological subtypes of ovarian cancer seem to originate in the fallopian tube 
epithelial or precursor lesions in the ovaries. Therefore a 2-pier system was proposed, 
with type I tumors being diagnosed usually in younger patients and at earler stages, 
and having a longer course and type II tumors with HGSOC as prototype, being usually 
diagnosed in advanced stages and having an aggressive course (23).  
We evaluated the impact of histological type on surgical and clinical outcome after 
primary tumor debulking EOC patients, in a retrospective cohort of patients. All 
patients have been operated by four experienced gynecological oncologists, in a 
comprehensive center for ovarian cancer with special training in abdominal surgery. 
Therefore the bias due to insufficient surgical skills can be excluded.  
Our study was performed retrospectively, but used a validated and systematic 
documentation tool, such as IMO. Hereby tumor pattern, surgical procedures and 
tumor residuals are described and are documented prospectively through an interview 
with the surgeon immediately during and after surgery. 
The results demonstrated that type I patients were significantly younger at time of first 
diagnoses compared with type II patients, and were diagnosed at earlier FIGO stages. 
Ascites, lymph node involvement had a lower incidence in type I patients, therefore 
even higher rates of optimal tumor debulking, less complications and shorter surgical 
times could be achieved. When the subanalysis was performed only in advanced stages 
(FIGO III and IV) the histological type didn’t retain any statistical significance, and 
had no prognostic value on survival rates or surgical outcome. When focusing on 
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advanced stages only the presence of a mucinous histology had a negative impact on 
survival when compared with low-grade serous tumors. Extrapelvic dissemination was 
more often encountered in  the presence of high-grade serous histology.  
According to the current guidelines primary EOC patients will be treated with 
Paclitaxel/Carboplatin with or without bevacizumab. Although there is enough 
evidence that low-grade tumors, clear cells and mucinous ovarian cancer do not 
respond well to platinum based chemotherapy, histological subtyping is still not taken 
into consideration in decision making process in primary setting (140). Wimberger et 
al presented the results of a retrospective large cohort analysis, where the multivariate 
analysis of OS identified following independent prognostic factors: mucinous 
histological subtype together with surgical outcome, multiple sites of metastases and 
ECOG status (141).  
According to the ovarian tumorigenesis theory, mucinous and clear cell subtypes are 
associated with better survival rates. This was the case in our study, but this was mainly 
due by being diagnosed in early stages. When the analysis was performed only for 
advanced stages the histological subtype did not retain its significance any more.  
When performing a sub analysis of only in optimal debulked patients, in terms of no 
macroscopically residuals, type II histology was associated with significantly poor 
survival. This might be explained by a potential ‘higher aggressiveness’ of type II 
cancers that might be associated with mutant p53. Nevertheless the exact underlying 
mechanisms have to be investigated in future trials. In the study by Eltabbakha et al it 
was found that p53 expression by immunhistochemical staining was a highly 
significant predictor for cytoreductibility. Complete cytoreduction was 5.6 times more 
likely to be achievied in women with tumors expressing p53 in a mild or moderate 
setting compared with the ones with stronger p53 expression (142). 
In a further study we analyzed the tumor pattern in paired, primary and relapse 
debulking surgery, in order to better understand the role and the limitations of 
secondary cytoreduction, and also to maybe detect clinical patterns that might predict 
resection. Our study revealed that cytoreduction was associated with larger tumor 
residuals after secondary cytoreduction, due to relapses in patterns less accessible to 
complete resection, such as mesentery, upper abdomen and gastrointestinal serosa. No 
other predictors for surgical outcome have been identified. Residual masses after 
primary and secondary cytoreduction correlated significantly.  
Our results showed that there is a different tumor spread in primary vs. relapse setting, 
with poor surgical outcome in relapse situation. This suggesting a more aggressive way 
of re-appearance of the disease, maybe due to clones diversity. Furthermore we 
detected no clinical parameters, or tumor spread in the primary setting that could 
predict the type of relapse onset.  
There are hints that platinum resistance may be attributed to originally preexisting 
clones that are present already by the time of first diagnosis (143). These clones will 
become more present with every relapse and will be responsible for the acquired 
platinum resistance. This theory might also explain the different tumor pattern in 
primary and relapse situation on same patients, making surgery more difficult and more 
extensive in order to be able to achieve no macroscopically residual disease.   
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In the relapse situation lower ascites volumes have been observed but also lower 
maximal tumor debulking rates. Retrospective data have showed the role of 
cytoreduction surgery at relapse, when patients seem to benefit if macroscopically 
tumor clearance is reached (68, 69, 99, 101). Although in relapse situation, patients 
were pretreated, the morbidity rates were not increased significantly, those data being 
in concordance with DESKTOP results published by Harter et al (68). We observed a 
trend of increase morbidity rates associated with secondary debulking, although no 
statistical significance has been reached. Therefore the indication for secondary 
cytoreduction must be well balanced and performed in optimal setting in order not to 
harm the patients. Until now, unfortunately, we have not yet reliable clinical, imagistic 
or serologic markers to predict surgical outcome.  
Furthermore we analyzed the role of HE4 alone or in combination with CA125 in the 
prognoses of surgical outcome after primary or secondary debulking. Most of the 
studies focused until now on the diagnostic role of HE4. There are few data about its 
role in predicting surgery outcome (144).  
If ovarian cancer cells or the tumor environment mostly overexpress HE4 and CA125, 
the removal of the tumor should be translated to postoperative reduction of the 
circulatory levels of HE4 and CA125. Also, higher serum HE4 and CA125 in EOC 
patients should reflect the extensive tumor pattern and persisting higher circulatory 
tumor marker values could be a sign of suboptimal tumor debulking.  
In our studies, in primary setting CA125 was performing slightly better than HE4 in 
predicting surgical outcome, but the combination of these both biomarkers slightly 
increased the sensitivity and specificity. For primary EOC HE4 and CA125 did not 
impact the OS and PFS. In the multivariate analysis only CA125 and FIGO stage II 
were independent predictive biomarkers for surgical outcome.  
Previous studies analyzed the role of CA125 in predicting surgical outcome in primary 
ovarian cancer patients. However, there is no established CA125 cut-off value to 
predict surgical outcome. Chi et al analyzed the CA125 cut-off value of 500 U/ml, 
showing a sensitivity and specificity of 78% and of 73%, respectively in predicting 
preoperative residual disease (145). Other studies have demonstrated that a decrease of 
more than 75 % in CA-125 levels from primary debulking to the start of adjuvant 
chemotherapy was associated with better PFS rates in EOC patients (146).  
In a recent publication by Angioli et al. combing preoperative HE4 levels (cut off value 
of 262pM), together with presence of ascites (less or more than 500ml) resulted in a 
sensitivity of 100% and a specificity of 89.5%, with a positive predicting value of 94% 
and negative predicting value of 100% (144). These results are much different from 
what we generated within our study, and this can be explained by the fact that Angioli, 
strongly preselected the patients. All patients underwent prior to study inclusion 
through a diagnostic laparoscopy. The laparoscopy consisted a triage to identify 
patients more likely to be optimal debulked or in being candidates for neoadjuvant 
treatment. The predictive role of HE4 for surgical outcome was evaluated only in the 
first group of patients. Angioli analyzed a significant lower number of preselected 
patients.  
In the patients having first relapse of EOC and undergoing secondary cytoreduction, 
the results showed that HE4 is an independent predictive factor for maximal tumor 
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debulking, and together with platinum response they are independent predictive factors 
for OS.  
The DESKTOP III Study recruited more than 140 patients. The DESKTOP III trial is 
evaluating prospectively the role of tumor debulking followed by platinum based 
chemotherapy vs. platinum based chemotherapy alone in platinum sensitive patients 
with first relapse and positive AGO score (71). According to DESKTOP I and II 
clinical trials, the AGO score could predict patients who are most likely to be optimal 
secondary tumor debulked. AGO score consists only in clinical parameters: residual 
mass after first cytoreduction, volume of ascites and ECOG status. For further 
prospective trials, the combination of biomarkers (eg. HE4 and CA125) with clinical 
parameters (eg. AGO score) could improve the sensitivity and specificity of both tests.   
Our data showed that higher CA125 circulatory levels were more often detected in 
patients who experience relapse in the middle abdomen vs. patients with no relapse in 
this region. HE4 showed higher circulatory levels in the presence of upper abdomen 
relapse. These differences could be explained with regard to tumor heterogeneity (147) 
suggesting that CA125 and HE4 might predict tumor pattern at relapse. These data are 
insufficient for drawing conclusions and larger studies are needed.  
A study by Kong et al included 80 patients with primary EOC. Results showed that 
increased HE4 levels were significantly associated with poor PFS in multivariate 
setting (p = 0.0179) (148). 
Other data suggest that increased circulatory levels of HE4 are an independent 
prognostic factor for PFS and OS in primary EOC patients. (149)  
The two studies showed that HE4 and CA125 are predictive markers for surgical 
outcome, although sensitivity and specificity were relative low.  
There are preclinical data showing that HE4 might be responsible for tumor 
progression (38, 39). This might explain the correlation with OS, PFS but also with 
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5 Future directions 
 
The presented articles showed a possible role of Glycanes, HE4 and CA125 in early 
diagnosis of EOC. Furthermore HE4 and CA125 seem to predict surgical outcome in 
primary and relapse ovarian cancer patients. Nevertheless the here presented data need 
to be validated in a prospective multicenter study. Therefore we designed the 
prospective, multicenter BERLINER study, which is on going. Within this study, 
pelvic mass patients in whom surgical treatment is recommended are included. All 
patients will undergo a standardize ultrasound according to IOTA criteria. Clinical 
data, including menstrual status, family history, symptoms are documented. Within this 
study the diagnostic role of HE4 and Ca125 alone or in combination together with 
ultrasound criteria will be analyzed. Furthermore blood samples, serum and plasma, 
will be collected for validation of the GLYCOV algorithm but also for the discovery 
of further possible biomarkers. This study prospectively included more than 1300 
pelvic mass patients. CA125 and HE4 will be analyzed centralized in Labor Berlin. 
Together with gynecological departments at Charité, 5 other gynecological clinics from 
Vivantes are participating into this trial. In order to address the importance of 
biomarker velocity in around 25% of the pacients a second serum sample was collected. 
New biomarker discovery using in silico analysis of publicly available data together 
with gene expression, proteomics and immunohistochemistry are planned for the near 
future.  
In order to understand better the impact of histological subtypes on surgical outcome, 
omics should be applied in different tumors and correlated with surgical outcome in 
future studies. Furthermore, surgical outcome should be assessed according to P53 
status as well as BRCAness in the primary tumors.  
Tumor heterogeneity should be taken in consideration; therefore it is mandatory to 
analyze temporary and spatial heterogeneity. Hence paired samples from primary sites 
and metastatic lesions will be analyzed in same patients. Furthermore, genetic changes 
using a predefined gene panel set will be used in order to identify differences in paired 
primary and relapsed ovarian cancer samples, but also in serial relapses obtained from 
similar patients. For the paired primary and relapsed ovarian cancer patients, we 
identified within the OCTIPS consortium, a FP7 European project, more than 100 
patients, where both primary and relapse samples are available. BRCAness in paired 
primary and relapse samples is of major clinical interest due to importance of 
companion diagnosis for therapy with PARP inhibitors.  
Furthermore we will analyze the dissemination pattern in OCTIPS patients, this time 
also with regard to patients receiving interval debulking surgery vs. primary debulking 
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6 Abstract 
 
Although a plethora of biomarkers have been analyzes in the last decades and 
ultrasound criteria have been developed, ovarian cancer is mostly diagnosed in 
advanced stages.  
Despite more extensive surgical procedures and improvement in surgical outcome, 
ovarian cancer remains a deadly disease with most of the patients developing relapse 
and platinum resistance.  
Although progresses in understanding the molecular biology of EOC have been done 
in the last years, targeted therapies failed to improve overall survival rates in ovarian 
cancer patients.  
The here presented data focuses on three major bottle necks of multimodal 
management of ovarian cancer: predictive biomarkers for early diagnosis of EOC, role 
and limitations of BRCA1 epigenetic changes and predictive biomarkers and clinical 
parameters for clinical outcome.  
Borderline tumors of the ovary (BOT) are a special entity of epithelial tumors, usually 
having a benign behavior. Nevertheless, optimal surgical staging is mandatory, as BOT 
could be a precursor of low grade serous ovarian cancers. Using ultrasound, BOT 
together with some benign tumors, are the most difficult pelvic tumors to be assessed. 
They have both malignant as also benign characteristics. In our study, presented here, 
we analyzed the role of HE4 and CA125 alone and in combination within ROMA 
algorithm to predict the presence of BOT in pelvic mass patients. Our results showed 
that HE4 and ROMA (an algorithm combining CA125, Both biomarkers together with 
ROMA had poor sensitivity and specificity. Therefore there is still an urgent need of 
new diagnostic strategies with regards to BOT.  
Furthermore we analyzed the role of GLYCOV for the diagnosis of early ovarian 
cancer. GLYCOV is a newly discovered biomarker panel, formed by 11 N-glycan 
biomarkers, more specific four high-mannose and seven complex-type fucosylated N-
glycans. Regarding to available data CA125 is increased in up to 80% of ovarian cancer 
patients, but only in 50% of early stages. Therefore CA125 remains a poor biomarker 
for early detection. In our study, GLYCOV had a better sensitivity and specificity than 
CA125 alone, with an AUC of 0.992 in detecting early stages EOC (FIGO stage I and 
II). This study included 20 FIGO I and II ovarian cancer patients, therefore further 
validation studies are needed.  
Homologous recombination deficiency (HRD) has been reported in up to 50% of high 
grade serous ovarian cancer patients. Mutations in BRCA1 and 2 genes are usually 
responsible for HRD. Epigenetic changes of BRCA1/2 promoter as also functional loss 
of proteins involved in HDR showed similar behavior as BRCA1/2 mutant tumors. 
Current trials showed that PARP inhibition increased progression free survival in 
BRCA mutant tumors. Therefore understanding inactivation mechanisms of the 
BRCA1 gene is of high clinical importance. In our study, we showed that methylation 
of BRCA1 promoter gene in HGSOC was not associated with platinum response, or 
with better overall or progression free survival rates. Hyper-methylation was associated 
with younger age at first diagnosis. No significant correlation between methylation 
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status and surgical outcome have been detected.  
Residual mass after primary tumor debulking is an important prognostic factor. 
Optimal surgery can be achieved in ca. 60-70% of the patients, if primary debulking is 
performed in high volume centers. Nevertheless in a sub-group of patients optimal 
surgical outcome cannot be achieved. Until now there are no predictive biomarkers or 
clinical parameters for residual tumor mass. We analyzed the role of CA125 and HE4 
in predicting surgical outcome in primary EOC. CA125 performed better than HE4 
alone, but the combination of both biomarkers increased the sensitivity and specificity. 
When looking at different histological subtypes, we found out that in early stages, type 
I tumors have better survival rates, less extensive surgery, less extensive tumor spread. 
This was mostly due to diagnosis in early stages.  Nevertheless when analyzing only 
the advanced FIGO stages, there was no differences in survival rates between type I 
and type II EOC. In advanced stages, tumor residuals together with positive lymph 
nodes and extrapelvic dissemination were independent prognostic factors for PFS and 
OS.  
If surgery is well accepted for primary situation, controversial discussions are 
surrounding the indication of secondary debulking surgery for ovarian cancer relapse. 
In our presented data, we analyzed the differences in surgical outcome and 
dissemination pattern in paired primary and relapse ovarian cancer patients. Complete 
tumor resection was significantly more often achieved in primary debulked patients as 
in first relapse. Residual mass at first surgery correlated with surgical outcome at 
relapse. No clinical parameters could predict surgical outcome in relapse situation. 
Dissemination pattern differed between primary and relapsed situation: with higher 
incidence of ascites at first diagnosis, and significant more involvement of upper 
abdomen in recurrent setting. In relapsed ovarian cancer diffuse mesenterial and 
peritoneal spread have been reported, leading to sub-optimal surgical outcome. There 
were no significant differences within postoperative complications.   
Looking for the classical biomarkers, HE4 and CA125, and their ability to predict 
surgical outcome, our study showed that both HE4 and CA125 are correlating with 
tumor residuals in patients with first platinum sensitive relapses. Nevertheless the 
sensitivity and specificity was poor, so further prospective multicentric studies 
evaluating biomarkers in combination with clinical parameters (eg. ECOG status, 
ascites, residual mass after primary debulking surgery) are needed. Furthermore, HE4 
together with response to first platinum based chemotherapy were the only independent 
prognostic factors for OS. 
These data are the fundament for further validation and discovery studies towards 
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